beta
Trial Radar AI

Let's discuss and explore clinical trials with GlaxoSmithKline as a lead sponsor or collaborator.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

12 Results
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
  
Biological Sex
Male
×
 
Phase
Phase 3
×
 
Type
Biological
×
 
Study Title
Status
Conditions
Other IDs
Lead Sponsor
Collaborators
Sites
Phase
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease NCT07220109
Not yet recruiting
A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) NCT06995430
Active, not recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study NCT06979323
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age NCT06855160
Recruiting
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age NCT06806137
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age NCT06740630
Recruiting
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age NCT06693895
Recruiting
A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) NCT06614725
Active, not recruiting
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study (RSV OA=ADJ=012) NCT06534892
Recruiting
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN) NCT05263934
Active, not recruiting